Precision BioSciences, Inc. (DTIL) is a publicly traded company in the Healthcare — Biotechnology industry listed on NASDAQ. This overview shows the latest price, key valuation ratios, profitability metrics and financial-health indicators used by fundamental investors.
Precision BioSciences, Inc. is a clinical-stage biotechnology firm based in the United States, specializing in the creation of both in vivo gene editing solutions and ex vivo allogeneic CAR T-cell therapies. At its core is ARCUS, a proprietary genome editing platform designed to address and potentially cure genetic diseases.
Analysis Summary
Precision BioSciences, Inc. reported revenue of $34.3M in the most recent fiscal year, growing at a 5-year CAGR of 7.1%.
Trailing-twelve-month margins: gross margin 100.0%, operating margin -80.8%, net margin -117.0%.
At the current price of $6.63, DTIL has negative trailing earnings (P/E not meaningful) and an ROE of -91.60%. Market capitalisation stands at $85M.
Balance sheet quality for DTIL: current ratio of 13.3, net cash position of $86.8M. A debt-to-equity below 1.0 typically signals conservative capital structure, while a current ratio above 1.5 indicates comfortable short-term liquidity.
Price
| Price | $6.63 |
| Market Cap | $85M |
| Exchange | NASDAQ |
| Country | US |
Valuation Ratios
| Price / Book | 3.78 |
| EV / EBITDA | -0.76 |
| Dividend Yield | 0.00% |
Profitability
| Return on Equity | -91.60% |
| Return on Invested Capital | -30.23% |
| Return on Assets | -41.88% |
| Gross Margin | 100.00% |
| Operating Margin | -80.78% |
| Net Margin | -117.04% |
Financial Health
| Debt / Equity | 0.62 |
| Current Ratio | 12.82 |
| Piotroski F-Score | 2 |
| Altman Z-Score | -4.31 |
What to look at in Biotech
Most small biotechs lose money. Analysing them with P/E makes no sense — look at cash and pipeline.
- Cash Runway — Months of cash at current burn rate. <18 months = urgent dilution risk
- Annual cash burn — Rate at which they burn operating cash. Compare with cash position to project runway
- Total Debt — Biotech with no revenue + debt = recipe for bankruptcy
- R&D / Market cap — How much they invest in pipeline vs the company value — research-intensity indicator
- Market cap / Cash — If it trades near its cash, the market assigns ~0 value to the pipeline — opportunity or trap
Peer Comparison
| Symbol | Company | Market Cap | P/E | P/B | ROE |
|---|---|---|---|---|---|
| DTIL | Precision BioSciences, Inc. | $85M | 3.78 | -91.6% | |
| 0QZU.L | Vertex Pharmaceuticals Incorporated | $131.8B | |||
| VRTX | Vertex Pharmaceuticals Incorporated | $130.3B | 29.68 | 6.45 | 23.3% |
| 0R2M.L | Regeneron Pharmaceuticals, Inc. | $84.0B | |||
| REGN | Regeneron Pharmaceuticals, Inc. | $79.8B | 18.79 | 2.57 | 13.8% |
| ARGX | argenx SE | $61.2B | 36.30 | 7.40 | 21.7% |
| MRNA | Moderna, Inc. | $57.8B | 1.34 | -39.2% | |
| RVMD | Revolution Medicines, Inc. | $41.7B | 15.96 | -96.4% |
Price Performance
| 1 month | -19.44% |
| 3 months | -2.64% |
| Year-to-date | +59.37% |
| 1 year | +46.36% |
| 3 years | -46.14% |
| 5 years | -98.28% |
52-Week Range
| 52-week High | $9.62 |
| 52-week Low | $3.53 |
| Avg Volume (90d) | 378K |
Related companies: ABOS · ALEC · GOSS · HOOK · HRTX · KLDO · QTTB
Explore sector: Healthcare · Biotechnology
More sections of DTIL: Financials · Valuation · Statistics · Estimates · Technical · Ownership · News · Events
Discover more: Radar — undervalued stock signals · Investment Academy — learn to analyze stocks